We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
MSD’s Keytruda has cut the risk of death by 31% in patients with esophageal or esophagogastric junction carcinoma or adenocarcinoma who progressed after standard therapy.